The clinical use of radiopharmaceuticals for SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography) is based on the pharmacodynamics and pharmacokinetics properties of radionuclide labelled molecules. The cellular and sub-cellular specific binding of radiopharmaceuticals helps in the diagnosis and therapy of several diseases by identifying the functional abnormality within tissues and cells. SPECT and PET imaging processing and analysis are crucial to obtain meaningful and quantitative data to classify disease stages and assess response to therapy regimens. Our team is dedicated to develop and use new radiopharmaceuticals, to improve radiation dosimetry incumbent to the use of internal radiation sources and to improve processing and analysis by developing software to classify and quantify disease due to cellular functional abnormalities.
To contribute for the continuous improvement of diagnostic and therapeutic capabilities with radiopharmaceuticals mainly in oncology and neuropsychiatry. To disseminate knowledge about Radiopharmacology and its application to Nuclear Medicine research and clinics.
Radiopharmaceutical imaging (SPECT and PET/CT); algorithms for radiation dosimetry; quantitative radiopharmaceutical imaging.
Oncology (brain, breast, gastrointestinal, gynecology, lung, prostate, skin); Neuropsychiatry (mood and affective disorders; neurodegenerative diseases, mainly dementias and movement disorders); Internal dosimetry; Quantitative radiopharmaceutical imaging.
If you are interested on joining our group or learn with us please contact Durval C. Costa and/or Francisco Oliveira at the email addresses below.